Ma Yinglong Report for the Third Quarter of 2024

SZSIOct 25 12:00 ET · Announcements

Mayinglong Pharmaceutical Group (600993.SH): The net income in the first three quarters was 0.458 billion yuan, a year-on-year increase of 9.35%.

Gelonghui October 25th | Mayinglong Pharmaceutical Group (600993.SH) released the third quarter report of 2024, with the company's revenue for the first three quarters reaching 2.792 billion yuan, a year-on-year increase of 14.13%; net income attributable to shareholders of the listed company was 0.458 billion yuan, a year-on-year increase of 9.35%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.449 billion yuan, a year-on-year increase of 24.62%; basic earnings per share was 1.06 yuan.

Gelonghui FinanceOct 25 04:19 ET

Mayinglong Pharmaceutical Group (SHSE:600993) Seems To Use Debt Rather Sparingly

Simply Wall StOct 24 19:03 ET

Mayinglong Pharmaceutical Group (SHSE:600993) Stock Performs Better Than Its Underlying Earnings Growth Over Last Five Years

Simply Wall StOct 6 20:40 ET

Calculating The Fair Value Of Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993)

Simply Wall StSep 18 21:36 ET

Founder Securities: Traditional Chinese medicine sector H1 performance is under short-term pressure. The performance of branded OTC companies is better than the industry as a whole.

Due to the impact of high base in the same period of 23Q2 and external factors such as centralized procurement and same-price policy, the performance of the traditional Chinese medicine sector in Q2 is under pressure compared to the same period last year, and it also declined compared to Q1.

Zhitong FinanceSep 8 04:48 ET